Macular Degeneration  >>  Soliris (eculizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT00935883: Complement Inhibition With Eculizumab for the Treatment of Non-Exudative Macular Degeneration (AMD)

Completed
2
60
US
Eculizumab, Soliris, Saline, PBS
Philip J. Rosenfeld, MD, PhD, Alexion Pharmaceuticals
Age-Related Macular Degeneration
06/12
08/13

Download Options